CELZ: Expands ADAPT Trial
Creative Medical Technology receives FDA clearance to expand its ADAPT clinical trial evaluating CELZ-201 for chronic lower back pain associated with degenerative disc disease
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
CELZ Expands ADAPT Trial
Creative Medical Technology Holdings expands ADAPT trial under new FDA clearance and advances toward Phase 3 planning for Olastrocel in chronic lower back pain